US Fails to Produce Medical Gloves After Spending Nearly $1 Billion

The United States has spent nearly $1 billion in efforts to revive domestic production of medical gloves, yet remains unable to manufacture them at scale. The initiative, driven by supply chain vulnerabilities exposed during the COVID-19 pandemic, has faced persistent challenges including high labor costs, lack of raw material supply chains, and technical difficulties in automating production. Despite government subsidies and private investment, no facility has achieved commercial viability. The U.S. currently imports over 90% of its medical gloves, primarily from Malaysia and Thailand. The failure underscores the difficulty of reshoring critical medical supplies after decades of offshoring.

Global Impact

Economically, the failure reinforces the dominance of Southeast Asian glove producers (Top Glove, Hartalega) and may lead to higher import prices if the U.S. imposes tariffs or quotas to protect domestic industry. Politically, it weakens the case for aggressive reshoring mandates, potentially shifting policy toward stockpiling and trade diversification rather than domestic production.